Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update
View original at globenewswire.comChemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update ─Completed Successful FDA End-of-Phase 2 Meeting Following Positive Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis (PSC)─ ─Achieved Alignment with FDA on Clear and Efficient Pathw…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Phase 2 SPRING trial data viewed by many experts as the strongest to date in PSC
60% confidenceNebokitug may halt or slow disease progression and improve clinical outcomes
60% confidenceUsing a clinical event-driven endpoint helps de-risk the Phase 3 program
60% confidenceEvaluating additional therapeutic indications where nebokitug has generated robust preclinical efficacy signals
60% confidenceCurrent cash runway expected to take company through end of Q1 2027
60% confidenceNebokitug has potential to become first disease-modifying treatment for PSC
60% confidenceDiscussions with potential strategic partners continue to advance
60% confidence2025 was a critical year for Chemomab and the nebokitug program
60% confidenceKey publications have linked PSC-related biomarker improvements in SPRING trial with reductions in clinical events
60% confidence